Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Bare-metal stent Stories

2013-08-09 23:21:22

“Research on China Coronary Stent Industry, 2013-2017” and “Global Coronary Stents - Market Growth Analysis 2009-2015” are market research reports available at ReportsnReports.com store. Dallas, TX (PRWEB) August 09, 2013 The recent research report “Research on China Coronary Stent Industry, 2013-2017” takes a view that, from the aspects of market scale, the annual growth rate of stent system will remain 8% globally on the whole. At present, cardiac Interventional surgeries in...

2013-07-15 23:16:40

Transparency Market Research Published new "Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 - 2016)" market research report to its report store. Browse the report; visit http://www.transparencymarketresearch.com/coronary-stents-market.html Albany, New York (PRWEB) July 15, 2013 According to Transparency Market Research “Global Drug Eluting (DES), Bare Metal (BMS) and Other Coronary Stents Market (2011 – 2016)”Global Coronary Stents market...

2013-03-14 12:27:36

CHICAGO, March 14, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boston Scientific (NYSE:BSX), Abbott Laboratories (NYSE:ABT), Cyberonics Inc. (Nasdaq:CYBX), Given Imaging. (Nasdaq:GIVN) and Aflac Inc. (NYSE:AFL). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get the...

2013-01-28 20:21:55

SINGAPORE, Jan. 28, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom(TM). BioFreedom represents the latest development in Biosensors' stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus...

2012-11-07 08:28:52

SINGAPORE, Nov. 7, 2012 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the second quarter of fiscal year 2013 (Q2 FY13) and the fiscal six months ended 30 September 2012 (H1 FY13). Q2 FY13 and Recent Highlights: Total revenue of US$79.8 million, representing 28% year-on-year growth Interventional...

2012-11-06 08:27:45

DURHAM, N.C., Nov. 6, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company's surface and polymer modification technology. This intellectual property protection is related to Micell's investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), as well as potential additional biomedical products. The patent rights are assigned to and...

2012-10-25 11:09:17

Results of the MASTER trial reported at TCT 2012 and published in JACC A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty. Results of the MASTER trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and will appear in...

2012-10-23 15:24:23

DURHAM, N.C., Oct. 23, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced positive data from two clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed to control drug release. Eighteen-month outcomes from the DESSOLVE I trial, and nine-month data supporting all study endpoints in the DESSOLVE II trial, were...

2012-10-16 07:27:12

DURHAM, N.C., Oct. 16, 2012 /PRNewswire/ -- Micell Technologies, Inc. today announced that data from clinical studies of its investigational MiStent(®) Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(TM)) will be presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium to be held in Miami, Fla. on October 22 - 26, 2012. David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer for the Piedmont...

2012-06-04 02:26:24

NATICK, Mass., June 4, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has provided Boston Scientific Corporation (NYSE: BSX) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element((TM)) Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug and...